430 related articles for article (PubMed ID: 19644623)
21. Patterns of disease modifying antirheumatic drug use in a Spanish cohort of patients with rheumatoid arthritis.
Gonzalez-Alvaro I; Carmona L; Balsa A; Sanmarti R; Belmonte MA; Tena X;
J Rheumatol; 2003 Apr; 30(4):697-704. PubMed ID: 12672186
[TBL] [Abstract][Full Text] [Related]
22. Methotrexate in rheumatoid arthritis is frequently effective, even if re-employed after a previous failure.
Kapral T; Stamm T; Machold KP; Montag K; Smolen JS; Aletaha D
Arthritis Res Ther; 2006; 8(2):R46. PubMed ID: 16507172
[TBL] [Abstract][Full Text] [Related]
23. Adverse events with disease modifying antirheumatic drugs (DMARD): a cohort study of leflunomide compared with other DMARD.
Cannon GW; Holden WL; Juhaeri J; Dai W; Scarazzini L; Stang P
J Rheumatol; 2004 Oct; 31(10):1906-11. PubMed ID: 15468352
[TBL] [Abstract][Full Text] [Related]
24. Prescription rheumatology practices among Mexican specialists.
Goycochea-Robles MV; Arce-Salinas CA; Guzmán-Vázquez S; Cardiel-Ríos MH
Arch Med Res; 2007 Apr; 38(3):354-9. PubMed ID: 17350489
[TBL] [Abstract][Full Text] [Related]
25. Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study.
Gibofsky A; Palmer WR; Goldman JA; Lautzenheiser RL; Markenson JA; Weaver A; Schiff MH; Keystone EC; Paulus HE; Harrison MJ; Whitmore JB; Leff JA
Curr Med Res Opin; 2006 Jan; 22(1):169-83. PubMed ID: 16393443
[TBL] [Abstract][Full Text] [Related]
26. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study.
van Halm VP; Nurmohamed MT; Twisk JW; Dijkmans BA; Voskuyl AE
Arthritis Res Ther; 2006; 8(5):R151. PubMed ID: 16984661
[TBL] [Abstract][Full Text] [Related]
27. Prognostic factors in a large cohort of patients with early undifferentiated inflammatory arthritis after application of a structured management protocol.
Quinn MA; Green MJ; Marzo-Ortega H; Proudman S; Karim Z; Wakefield RJ; Conaghan PG; Emery P
Arthritis Rheum; 2003 Nov; 48(11):3039-45. PubMed ID: 14613264
[TBL] [Abstract][Full Text] [Related]
28. [Descriptive study of the use of DMARD in patients with rheumatoid arthritis or persistent arthritis who start drug treatment in Spain (FIRST)].
Blanco FJ; Ballina J; Carbonell J; Martín-Mola E; Tornero J; Ramírez E; Galván J
Reumatol Clin; 2011; 7(2):88-93. PubMed ID: 21794790
[TBL] [Abstract][Full Text] [Related]
29. Risk factors associated with the cumulative survival of low-dose methotrexate in 273 Japanese patients with rheumatoid arthritis.
Ideguchi H; Ohno S; Ishigatsubo Y
J Clin Rheumatol; 2007 Apr; 13(2):73-8. PubMed ID: 17414533
[TBL] [Abstract][Full Text] [Related]
30. Daily practice effectiveness of a step-down treatment in comparison with a tight step-up for early rheumatoid arthritis.
Verschueren P; Esselens G; Westhovens R
Rheumatology (Oxford); 2008 Jan; 47(1):59-64. PubMed ID: 18039681
[TBL] [Abstract][Full Text] [Related]
31. Practice variation in the treatment of rheumatoid arthritis among German rheumatologists.
Zink A; Listing J; Ziemer S; Zeidler H;
J Rheumatol; 2001 Oct; 28(10):2201-8. PubMed ID: 11669156
[TBL] [Abstract][Full Text] [Related]
32. Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis.
James HM; Gillis D; Hissaria P; Lester S; Somogyi AA; Cleland LG; Proudman SM
J Rheumatol; 2008 Apr; 35(4):562-71. PubMed ID: 18322994
[TBL] [Abstract][Full Text] [Related]
33. Can disease-modifying anti-rheumatic drugs be discontinued in long-standing rheumatoid arthritis? A 15-year follow-up.
Tiippana-Kinnunen T; Paimela L; Kautiainen H; Laasonen L; Leirisalo-Repo M
Scand J Rheumatol; 2010; 39(1):12-8. PubMed ID: 20132065
[TBL] [Abstract][Full Text] [Related]
34. Prescribing trends in disease modifying antirheumatic drugs for rheumatoid arthritis: a survey of practicing Canadian rheumatologists.
Pope JE; Hong P; Koehler BE
J Rheumatol; 2002 Feb; 29(2):255-60. PubMed ID: 11838842
[TBL] [Abstract][Full Text] [Related]
35. A more active treatment has profound effects on the health status of rheumatoid arthritis (RA) patients: results from a population-based RA register in Malmö, Sweden, 1997-2005.
Söderlin MK; Lindroth Y; Turesson C; Jacobsson LT
Scand J Rheumatol; 2010 May; 39(3):206-11. PubMed ID: 20001765
[TBL] [Abstract][Full Text] [Related]
36. Disease modifying antirheumatic drugs in early rheumatoid arthritis: a longterm observational study.
Papadopoulos NG; Alamanos Y; Papadopoulos IA; Tsifetaki N; Voulgari PV; Drosos AA
J Rheumatol; 2002 Feb; 29(2):261-6. PubMed ID: 11838843
[TBL] [Abstract][Full Text] [Related]
37. Providing patients with information about disease-modifying anti-rheumatic drugs: Individually or in groups? A pilot randomized controlled trial comparing adherence and satisfaction.
Homer D; Nightingale P; Jobanputra P
Musculoskeletal Care; 2009 Jun; 7(2):78-92. PubMed ID: 18792423
[TBL] [Abstract][Full Text] [Related]
38. Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies.
Saunders SA; Capell HA; Stirling A; Vallance R; Kincaid W; McMahon AD; Porter DR
Arthritis Rheum; 2008 May; 58(5):1310-7. PubMed ID: 18438851
[TBL] [Abstract][Full Text] [Related]
39. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis.
Nell VP; Machold KP; Eberl G; Stamm TA; Uffmann M; Smolen JS
Rheumatology (Oxford); 2004 Jul; 43(7):906-14. PubMed ID: 15113999
[TBL] [Abstract][Full Text] [Related]
40. The influence of medication beliefs and other psychosocial factors on early discontinuation of disease-modifying anti-rheumatic drugs.
Wong M; Mulherin D
Musculoskeletal Care; 2007 Sep; 5(3):148-59. PubMed ID: 17590885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
